Last reviewed · How we verify
NCT06925451
Effects of Sourdough Fermentation Duration and Acid Development on Postprandial Blood Glucose in Prediabetic Adults
NA trial testing sourdough bread 24 in Insulin Resistance in 5 participants. Completed in 15 December 2025.
15 August 2025
Quick facts
| Lead sponsor | Arizona State University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | single |
| Primary purpose | other |
| Enrollment | 5 |
| Start date | 4 April 2025 |
| Primary completion | 15 August 2025 |
| Estimated completion | 15 December 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- sourdough bread 24
- sourdough bread 48
- sourdough bread 72
- yeast bread
Conditions studied
- Insulin Resistance — all drugs for Insulin Resistance →
Sponsor
Arizona State University
Who can join
18 and older, any sex, with Insulin Resistance. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary intervention for management of prediabetes is lifestyle changes. Eating healthier and increasing physical activity was found to slow the progression of prediabetes into diabetes, reduce the risk of other diseases like cardiovascular disease and hypertension, and have a lasting impact even after the intervention is discontinued. Studies found that increasing the intake of fiber, pre- and probiotics, and fermented foods have been linked to improved glycemic biomarkers. The goal of this crossover randomized trial is to assess the relationship between lengthened fermentation time of sourdough bread, e.g., an increased amount of lactic acid and acetic acid in the bread product, and postprandial glycemic response in healthy adults with prediabetes.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06925451
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Insulin Resistance
Currently open trials in the same condition.
- NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
- NCT07226128 — The Effects of Cognitive Behavioral Therapy on Insulin Resistance in People With HIV · NA · recruiting
- NCT07505745 — MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity · Phase 2 · recruiting
- NCT07220694 — Effects of Sabroxy® Supplementation on Insulin Resistance and Cognitive Function in Adults With Mild Cognitive Impairmen · NA · recruiting
- NCT06768827 — New Mechanisms of Obesity · NA · recruiting
Other Arizona State University trials
Trials by the same sponsor.
- NCT07519408 — Acute Kidney Injury and Ultra-endurance Running · NA · not yet recruiting
- NCT05784467 — Methamphetamine, PrEP, and Intersectional Stigma Study · NA · not yet recruiting
- NCT07375043 — Drumming Groups for Parents of Autistic Children · NA · not yet recruiting
- NCT07297901 — App-based Breathing Program for Migraine Relief · NA · enrolling by invitation
- NCT06721793 — The Impact of a Caffeinated Sports Drink on Performance · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06925451 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Arizona State University
- Last refreshed: 23 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06925451.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing